Antibody drug conjugate (ADC) research involves more and more targets, such as HER-2, Trop-2, Claudin-18.2, B7-H3 and B7-H4, etc. Trop-2 is a transmembrane glycoprotein. Its high expression is associated with the […]
Alzheimer’s disease (AD) is a very common neurodegenerative disease in old age, which not only affects the patient’s thinking, memory and independence, but also leads to a decline in the quality of […]
A prodrug, also known as a precursor drug, generally refers to a class of compounds that are themselves inactive or have weak activity but, after conversion within a biological organism, […]
Targeted protein degradation (TPD) is an emerging protein degradation technology in recent decades that utilizes the cell’s own protein clearance mechanisms, such as lysosomal degradation and proteasomal degradation, to degrade target […]
Antibody-drug conjugate (ADC) combines the tumor targeting specificity of monoclonal antibodies and the potent cell killing activity of cytotoxic drugs (warhead/payload), through a carefully designed chemical linker (linker). The two are […]
The emergence of RNA synthesis in vitro and in vivo delivery methods has garnered significant attention in the biomedical field, particularly regarding the applications of synthetic mRNA. However, in most biological […]
Nucleic acid drugs are mainly divided into two major categories: small nucleic acid drugs and mRNA. Small nucleic acid drugs, also known as oligonucleotide drugs, include antisense nucleotides (ASO), small […]
Chemotherapy drugs are an important means of tumor treatment. At present, chemotherapy drugs based on different mechanisms have been developed, which can act on the initial raw materials such as […]
So far, the FDA and EMA have approved six ADC drugs for patients with solid tumors. Fig. 1 depicts the composition of each ADC (targeting antigen, mAb type, payload, and linker), […]
Covalent drugs refer to those drug molecules that form strong bonds with receptors through the formation of covalent bonds. It all began with aspirin in 1899, gained prominence with ibrutinib in […]